Skip to content

The effect of intravenous sodium valproate versus dexamethasone on acute migraine headache

The effect of intravenous sodium valproate versus dexamethasone on headache relief in patients with acute migraine headache: a double blinded randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201202199014N1
Enrollment
72
Registered
2012-03-24
Start date
2012-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute migraine headache. Migraine with or without aura

Interventions

Intervention 1: Intervention 1: A single dose of 400 mg sodium valproate plus 50 mL saline normal solution within 15 min intravenously. Intervention 2: Intervention 2: A single dose of 16 mg dexametha
Treatment - Drugs
Intervention 1: A single dose of 400 mg sodium valproate plus 50 mL saline normal solution within 15 min intravenously.
Intervention 2: A single dose of 16 mg dexamethasone plus 50 mL saline normal solution within 15 min intravenously.

Sponsors

Vic-Chancellor of Research and Technology, Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 18 to 65 years; history of having migraine for at least one year; severity of headache equal to or greater than 5 VAS

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of headache. Timepoint: At baseline and then 0.5 hour and 2 hours later. Method of measurement: Visual Analogue Scale (VAS).

Secondary

MeasureTime frame
Any side effect such as allergy. Timepoint: 0.5 hour and 2 hours later. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJalal Poorolajal

Research Center for Health Sciences, Department of Epidemiology & Biostatistics

poorolajal@umsha.ac.ir+98 81 1838 0090

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 5, 2026